Organization
The Fifth Medical Center of Chinese PLA General Hospital
7 abstracts
Abstract
A novel and selective oral PI3Kα/δ inhibitor, TQ-B3525, in patients with relapsed and/or refractory follicular lymphoma: A phase II, single-arm, open-label study.Org: The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tongji Hospital of Tongji University, The Affiliated Cancer Hospital of Nanjing Medical University, The Affiliated Hospital of Inner Mongolia Medical College,
Abstract
Dalpiciclib and chidamide in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China,
Abstract
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.Org: BeiGene (Shanghai) Co., Ltd., The Fifth Medical Center of Chinese PLA General Hospital,
Abstract
Clinicopathological characteristics, treatment patterns, and prognosis of male breast cancer: China versus the United States.Org: Breast Disease Center, West China Hospital, Sichuan University, The First Affiliated Hospital of Sun Yat-sen University, The Fifth Medical Center of Chinese PLA General Hospital,
Abstract
A comparison between a clinical decision support system and clinicians with guidelines in breast cancer.Org: Fifth Medical Center of PLA General Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Affiliated Hospital of Hebei University, Baoding, China, Fourth Affiliated Hospital of Hebei Medical University,
Abstract
A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Department of Gastroenterology and Urology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Harbin Medical University Cancer Hospital,
Abstract
Donafenib, anti-PD-1 antibodies, plus hepatic arterial infusion chemotherapy (HAIC) as conversion therapy in patients with initially unresectable hepatocellular carcinoma (HCC): A prospective, single-arm, phase 2 study.Org: The Fifth Medical Center of the PLA General Hospital, The Fifth Medical Center of Chinese PLA General Hospital,